Coating with a Modular Bone Morphogenetic Peptide Promotes Healing of a Bone-Implant Gap in an Ovine Model

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Lu, Yan ^a,c   Lee, Jae Sung ^b   Nemke, Brett ^a   Graf, Ben K ^c   Royalty, Kevin ^b   Illgen III, Richard ^c   Vanderby, Ray ^b   Markel, Mark D ^a,c   Murphy, William L ^b,c  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN; HYDROXYAPATITE; MODULAR BONE MORPHOGENETIC PEPTIDE; TITANIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING KINETICS; BONE IMPLANT; BONE IMPLANT GAP; BONE MINERALIZATION; BONE PEAK FORCE; BONE PUSH OUT STIFFNESS; BONE RADIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE MODEL; DRUG BINDING; FEMALE; FEMUR CONDYLE; FRACTURE FIXATION; FRACTURE HEALING; HISTOPATHOLOGY; MICRORADIOGRAPHY; MUSCULOSKELETAL SYSTEM PARAMETERS; NONHUMAN; OSSIFICATION; SHEEP; SUSTAINED DRUG RELEASE;

EID: 84869842199     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050378     Document Type: Article

References (33)

1. Bozic KJ, Kurtz SM, Lau E, Ong K, Chiu V, et al. (2010) The epidemiology of revision total knee arthroplasty in the United States. Clin Orthop Relat Res 468: 45-51.
2. Elmengaard B, Bechtold JE, Chen X, Soballe K, (2009) Fixation of hydroxyapatite-coated revision implants is improved by the surgical technique of cracking the sclerotic bone rim. J Orthop Res 27: 996-1001.
3. Daugaard H, Elmengaard B, Bechtold JE, Soballe K, (2008) Bone growth enhancement in vivo on press-fit titanium alloy implants with acid etched microtexture. J Biomed Mater Res A 87: 434-440.
4. Sachse A, Wagner A, Keller M, Wagner O, Wetzel WD, et al. (2005) Osteointegration of hydroxyapatite-titanium implants coated with nonglycosylated recombinant human bone morphogenetic protein-2 (BMP-2) in aged sheep. Bone 37: 699-710.
5. Lamberg A, Schmidmaier G, Soballe K, Elmengaard B, (2006) Locally delivered TGF-beta1 and IGF-1 enhance the fixation of titanium implants: a study in dogs. Acta Orthop 77: 799-805.
6. Hollister SJ, Murphy WL, (2011) Scaffold translation: barriers between concept and clinic. Tissue Eng Part B Rev 17: 459-474.
7. Peng S, Zhou G, Luk KD, Cheung KM, Li Z, et al. (2009) Strontium promotes osteogenic differentiation of mesenchymal stem cells through the Ras/MAPK signaling pathway. Cell Physiol Biochem 23: 165-174.
8. Boden SD, Zdeblick TA, Sandhu HS, Heim SE, (2000) The use of rhBMP-2 in interbody fusion cages. Definitive evidence of osteoinduction in humans: a preliminary report. Spine (Phila Pa 1976) 25: 376-381.
9. Kanayama M, Hashimoto T, Shigenobu K, Yamane S, Bauer TW, et al. (2006) A prospective randomized study of posterolateral lumbar fusion using osteogenic protein-1 (OP-1) versus local autograft with ceramic bone substitute: emphasis of surgical exploration and histologic assessment. Spine (Phila Pa 1976) 31: 1067-1074.
10. Govender S, Csimma C, Genant HK, Valentin-Opran A, Amit Y, et al. (2002) Recombinant human bone morphogenetic protein-2 for treatment of open tibial fractures: a prospective, controlled, randomized study of four hundred and fifty patients. J Bone Joint Surg Am 84: 2123-2134.
11. Cahill KS, Chi JH, Day A, Claus EB, (2009) Prevalence, complications, and hospital charges associated with use of bone-morphogenetic proteins in spinal fusion procedures. JAMA 302: 58-66.
12. Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, et al. (2006) Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine (Phila Pa 1976) 31: 542-547.
13. Wong DA, Kumar A, Jatana S, Ghiselli G, Wong K, (2008) Neurologic impairment from ectopic bone in the lumbar canal: a potential complication of off-label PLIF/TLIF use of bone morphogenetic protein-2 (BMP-2). Spine J 8: 1011-1018.
14. Carragee EJ, Mitsunaga KA, Hurwitz EL, Scuderi GJ, (2011) Retrograde ejaculation after anterior lumbar interbody fusion using rhBMP-2: a cohort controlled study. Spine J 11: 511-516.
15. Carragee EJ, Hurwitz EL, Weiner BK, (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J 11: 471-491.
16. Liu Y, de Groot K, Hunziker EB, (2005) BMP-2 liberated from biomimetic implant coatings induces and sustains direct ossification in an ectopic rat model. Bone 36: 745-757.
17. Liu Y, Enggist L, Kuffer AF, Buser D, Hunziker EB, (2007) The influence of BMP-2 and its mode of delivery on the osteoconductivity of implant surfaces during the early phase of osseointegration. Biomaterials 28: 2677-2686.
18. Saito A, Suzuki Y, Ogata S, Ohtsuki C, Tanihara M, (2003) Activation of osteo-progenitor cells by a novel synthetic peptide derived from the bone morphogenetic protein-2 knuckle epitope. Biochim Biophys Acta 1651: 60-67.
19. Saito A, Suzuki Y, Kitamura M, Ogata S, Yoshihara Y, et al. (2006) Repair of 20-mm long rabbit radial bone defects using BMP-derived peptide combined with an alpha-tricalcium phosphate scaffold. J Biomed Mater Res A 77: 700-706.
20. Lee JS, Lee JS, Wagoner-Johnson A, Murphy WL, (2009) Modular peptide growth factors for substrate-mediated stem cell differentiation. Angew Chem Int Ed Engl 48: 6266-6269.
21. Lee JS, Lee JS, Murphy WL, (2010) Modular peptides promote human mesenchymal stem cell differentiation on biomaterial surfaces. Acta Biomater 6: 21-28.
22. Elmengaard B, Bechtold JE, Soballe K, (2005) In vivo effects of RGD-coated titanium implants inserted in two bone-gap models. J Biomed Mater Res A 75: 249-255.
23. Faria ML, Lu Y, Heaney K, Uthamanthil RK, Muir P, et al. (2007) Recombinant human bone morphogenetic protein-2 in absorbable collagen sponge enhances bone healing of tibial osteotomies in dogs. Vet Surg 36: 122-131.
24. Lu Y, Markel MD, Nemke B, Lee JS, Graf BK, et al. (2009) Influence of hydroxyapatite-coated and growth factor-releasing interference screws on tendon-bone healing in an ovine model. Arthroscopy 25: 1427-1434.
25. Shields LB, Raque GH, Glassman SD, Campbell M, Vitaz T, et al. (2006) Adverse effects associated with high-dose recombinant human bone morphogenetic protein-2 use in anterior cervical spine fusion. Spine 31: 542-547.
26. Campbell AW, Bain WE, McRae AF, Broad TE, Johnstone PD, et al. (2003) Bone density in sheep: genetic variation and quantitative trait loci localisation. Bone 33: 540-548.
27. Fini M, Giavaresi G, Greggi T, Martini L, Aldini NN, et al. (2003) Biological assessment of the bone-screw interface after insertion of uncoated and hydroxyapatite-coated pedicular screws in the osteopenic sheep. J Biomed Mater Res A 66: 176-183.
28. Lu Y, Nemke B, Lorang DM, Trip R, Kobayashi H, et al. (2009) Comparison of a new braid fixation system to an interlocking intramedullary nail for tibial osteotomy repair in an ovine model. Vet Surg 38: 467-476.
29. Rammelt S, Heck C, Bernhardt R, Bierbaum S, Scharnweber D, et al. (2007) In vivo effects of coating loaded and unloaded Ti implants with collagen, chondroitin sulfate, and hydroxyapatite in the sheep tibia. J Orthop Res 25: 1052-1061.
30. Elmengaard B, Bechtold JE, Soballe K, (2005) In vivo study of the effect of RGD treatment on bone ongrowth on press-fit titanium alloy implants. Biomaterials 26: 3521-3526.
31. Kessler S, Mayr-Wohlfart U, Ignatius A, Puhl W, Claes L, et al. (2003) [The impact of bone morphogenetic protein-2 (BMP-2), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) on osseointegration, degradation and biomechanical properties of a synthetic bone substitute]. Z Orthop Ihre Grenzgeb 141: 472-480.
32. Suarez-Gonzalez D, Barnhart K, Migneco F, Flanagan C, Hollister SJ, et al. (2012) Controllable mineral coatings on PCL scaffolds as carriers for growth factor release. Biomaterials 33: 713-721.
33. Lee JS, Wagoner Johnson AJ, Murphy WL, (2010) A modular, hydroxyapatite-binding version of vascular endothelial growth factor. Adv Mater 22: 5494-5498.